Recent Comments
- Bill on The Declaration of Pandemics
- Margaret McGregor on The Declaration of Pandemics
- admin on A Surgeon’s Story: Decision-making
- Margaret McGregor on A Surgeon’s Story: Decision-making
- LB on Has Bobby Kennedy’s campaign been infiltrated by intelligence operations?
Most Viewed Posts
- Exclusive: Why the COVID “mRNA” vaccines are actually DNA gene therapies that must be removed from the market (17,651)
- Pfizer admits in federal court that the COVID gene therapies were never approved through the FDA (15,883)
- New treatment paradigm for C. Diff colitis (14,793)
- Gordon Guyatt, MD: Update on the problem of clinical trials being stopped early to inflate efficacy of drugs (14,766)
- I discuss the handling of the COVID-19 outbreak on The Joe Piscopo radio show (14,224)
- How the FDA regulates compounding pharmacies (14,072)
- The Healthcare Channel hits 10 (13,575)
- The new CDC guidelines for prescribing opioid pain pills (9,078)
- The Who’s Teen Cancer Lounge at Sloan Kettering opens (8,580)
- Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital. (8,290)
Pages
Categories
- – Biotech
- – Generics
- – JAMA
- – Medical Devices
- – NEJM
- – Opinion
- – Pharma
- – Policy
- – Reviews, books, devices
- – The Weekly Summary
- Bariatric surgery
- Cardiac surgery
- Cardiology
- Dermatology
- Diabetes and endocrinology
- Emergency medicine
- Gastroenterology and liver
- General surgery
- Genetics
- Geriatrics
- Infectious disease
- Internal Medicine
- Neurology
- Neurosurgery
- Obstetrics and Gynecology
- Oncology
- Ophthalmology
- Orthopedic surgery
- Pediatrics
- Plastic surgery
- Primary care medicine
- Psychology Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Spine surgery
- Sports medicine
- Transplant surgery
- Trauma Surgery
- Uncategorized
- Urology
- Vascular Surgery
- Z Medical centers
- Baylor
- Boston University
- Cedars Sinai
- Cleveland Clinic
- Columbia
- Cornell
- Duke
- Emory
- George Washington Univ
- Harvard
- Henry Ford
- Iowa State
- Johns Hopkins
- Mayo Clinic
- McMaster University
- Medical University of South Carolina
- Memorial Sloan-Kettering
- Michigan
- National Jewish Health
- NYU
- Ohio State
- Oregon Health and Science University
- UC Davis
- UC San Francisco
- UCLA
- Univ Kentucky
- Univ Maryland
- Univ Miami
- Univ Michigan
- Univ of Louisville
- Univ Texas
- VA Walter Reed
- Vanderbilt
- VCU
- Washington University
- Yale
Category Archives: – Biotech
Pfizer documents show vaccine causes high fetal death rates
February 3, 2022- by Steven E. Greer, MD
India, Mexico, and El Salvador distribute ivermectin to citizens in free COVID kits
January 20, 2022- by Steven E. Greer, MD As all hospitals in the U.S. refuse to administer lifesaving early treatments for the SARS-CoV-2 coronavirus,
What you need to know about the SARS-CoV-2 coronavirus vaccines
Update March 22, 2021- by Steven E. Greer, MD Tucker Carlson interviewed a surgeon who stated what I have known for many months. The signal
Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Infectious disease, Internal Medicine, NIH
Leave a comment
Sen. Ron Johnson on the need for early treatment of the Wuhan coronavirus
December 13, 2020- by Steven E. Greer, MD This is straight from my book, Tony’s Virus, chapters 8 and chapter 10.
The “surge in new Wuhan virus cases” is great news
June 26, 2020- by Steven E. Greer, MD I called it, once again. On June 9th, I wrote, “This unprecedented communist-party-like anarchy in
Are there any medications to treat coronavirus?
(Also: How infectious and lethal is this Coronavirus COVID-19 compared to regular “flu”?) February 27, 2020- by Steven E. Greer, MD Gilead makes a not-yet-approved antiviral drug called remdisivir and it is being tested right
Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Primary care medicine
2 Comments
60 Minutes creates another publicist-paid puff-piece for an unethical medical researcher
December 8, 2019- by Steven E. Greer, MD CBS’ 60 Minutes featured an extremely unethical PhD medical researcher at Harvard named George
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,
Preventing HIV infection
July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote
Paul Richardson, MD: Current Therapies for Multiple Myeloma
December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber
Posted in - Biotech, - Pharma, Harvard, Oncology
Leave a comment
Triple Therapy for Cystic Fibrosis
October 18, 2018- interviewed by Steven E. Greer, MD
BRAF and MEK combos for melanoma
Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year.
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Google wants your medical records
December 19, 2013- Interviewed by Steven E. Greer, MD In Part 3 of our interview with Robert Klitzman, MD, ethics professor at Columbia University,
Google’s Larry Page wants your medical records to be public for “research”
March 20, 2014-By Steven E. Greer, MD Charlie Rose interviewed Google founder Larry Page at the 2014 TED conference. During the talk, Mr.
Posted in - Biotech, - Medical Devices, - Opinion, Congress, Genetics
Leave a comment
Review of immunotherapy and targeted therapy
June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
The Year in Review: 2018
December 29, 2018- by Steven E. Greer, MD The biggest stories this year related
Insurance companies are not paying for Repatha and Praluent
Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.
Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis
January 31, 2017- Interviewed by Steven E. Greer, MD
Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas
Leave a comment
KIT inhibition by Gleevec (imatinib) for severe asthma
May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers
Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology
Leave a comment
Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways
March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment